BRAF^(V600E)与TERT启动子共同突变在甲状腺乳头状癌诊治中的临床意义

Clinical significance of co-mutation of BRAF^(V600E) and TERT promoter in diagnosis and treatment of papillary thyroid carcinoma

BRAF^(V600E)突变是甲状腺乳头状癌(papillary thyroid cancer,PTC)较常见的基因突变,与PTC的发生、发展及预后存在相关性。TERT启动子突变在PTC中少见,但伴有其突变的PTC具有侵袭性更强、预后更差的特点。临床上,少部分PTC患者同时伴有BRAF^(V600E)和TERT启动子突变,本文从BRAF^(V600E)和TERT启动子共同突变与PTC的发生发展、临床诊断、手术策略、术后辅助治疗及预后等方面进行简要阐述。

BRAF^(V600E) mutation is a common gene mutation in papillary thyroid carcinoma(PTC),which is associated with the occurrence,development,and prognosis of PTC.TERT promoter mutations are rare in PTC,but PTC with its mutations is more aggressive and has a worse prognosis.Clinically,a small number of PTC patients have both BRAF^(V600E) mutation and TERT promoter mutations.This article provides a brief overview of the co-mutation of BRAF^(V600E) and TERT promoter and the occurrence and development,clinical diagnosis,surgical strategies,postoperative adjuvant treatment,and prognosis of PTC.